The brain and its self: A neurochemical concept of the innate and acquired drives

The Brain and Its Self: A Neurochemical Concept of the Innate and Acquired Drives

Volumn , Issue , 2005, Pages 1-176

  Knoll, Joseph ^a  

^a NONE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84920182045     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-27434-0     Document Type: Book

References (224)

1. Ajika K, Hökfelt T (1973) Ultrastructural identification of catecholamine neurons in the hypothalamic preventricular arcuate nucleus-median eminence complex with special reference to quantitative aspects. Brain Res 57: 97-117.
2. Alajouanine T (1948) Aphasia and artistic realization. Brain 71:229-241.
3. Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366-375.
4. Allain H, Gougnard J, Naukirek HC (1991) Selegiline in de novo parkinsonian patients: The French selegilinemulticenter trial (FSMP). Acta Neurol Scand 136:73-78.
5. Amsterdam JD (2003) A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 64:208-214.
6. Ban TA, Healy D, Shorter E (1998) The rise of psychopharmacology and the story of CINP. Animula Publishing House, Budapest.
7. Bartov O (2001) In God's name: genocide and religion in the twentieth century (War and genocide, vol 4). Berghahn Books.
8. Beritov IC (1932) As cited in Knoll J (1969) The theory of active reflexes. Hungarian Academy of Sciences, Budapest; Hafner Publishing, New York, p 10.
9. Bertler A (1961) Occurrence and localization of catecholamines in human brain. Acta Physiol Scand 51:135-161.
10. Birkmayer W, Hornykiewicz O (1962) Der L-Dioxyphenyl-Alanin-Effekt beim Parkinson-Syndrom des Menschen. Arch Psychiat Nervenkrh 203:560-564.
11. Birkmayer W, Riederer P, Ambrozi L, Youdim MBH (1977) Implications of combined treatmentwith"Madopar" and L-deprenil in Parkinson's disease. Lancet 1:439-443.
12. Birkmayer W, Riederer P, Linauer W, Knoll J (1984) L-Deprenyl plus L-phenylalanine in the treatment of depression. J Neural Transm 59:81-87.
13. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton V (1985) Increased life expectancy resulting fromaddition of L-deprenyl toMadopar treatment in Parkinson's disease: A long-term study. J Neural Transm 64:113-127.
14. Birks J, Flicker L (2003) Selegiline for Alzheimer's disease. Cochrane Database Syst Rev 1:CE000442.
15. Blackwell B (1963) Hypertensive crisis due to monoamine oxidase inhibitors. Lancet ii:849-851.
16. Bodkin JA, Amsterdam JD (2002) Transdermal selegiline in major depression: A double-blind, placebo-controlled, parallel-group study in outpatients.Am J Psychiatry 159:1869-1875.
17. Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW(2000) Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 343:450-456.
18. Borowsky B, Adham N, Jones KA, Raddatz R, Artimishyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S, Boyle N, Pu X, Kouranova E, LichtblauH, Ochoa FY, Branchek TA, Gerald C (2001) Trace amines: Identification of a family of mammalian G protein-coupled receptors. Proc Nat Acad Sci USA 98: 8966-8971.
19. Borroni B, Archetti S, Agosti C, Akkawi N, Brambilla C, Caimi L, Caltagirone C, Di Luca M, Padovani A (2004) Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: From risk factors to disease modulators. Neurobiol Aging 25:747-751.
20. Boulton AA, Juorio AV, Downer RGH (1988) Trace amines: comparative and clinical neurobiology (Experimental and clinical neuroscience). Humana Press, Totowa, NJ.
21. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, Olson SB, Magenis RE, Amara SG, Grandy DK (2001) Amphetamine, 3, 4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60:1181-1188.
22. Calas A, Alonso G, Arnauld E, Vincent JD (1974) Demonstration of indolaminergic fibers in the median eminence of the duck, rat and monkey. Nature 250:242-243.
23. Calas A, Besson NJ, Cauchy C, Alonso G, Glowinsky J, Cheramy A (1976) Radioautographic study of in vivo incorporation of 3H-monoamines in the cat caudate nucleus:identification of serotoninergic fibers. Brain Res 118:1-13.
24. Campi N, Todeschini GP, Scarzella L (1990) Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia. Clin Ther 12:306-314.
25. Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M et al. (1999) Early-onset autosomal dominant Alzheimer disease: Prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 65:664-670.
26. Carlsson A (1979) The impact of catecholamine research on medical science and practice. In: Usdin E, Kopin IJ, Barchas J. (eds) Catecholamines: basic and clinical frontiers, vol 1. Pergamon Press, New York, pp 4-19.
27. Carrillo MC, Kanai S, Nokubo M, Kitani K(1991)(-)Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathion peroxidase in the striatum of young male rats. Life Sci 48:517-521.
28. Carrillo MC, Kanai S, Nokubo M, Ivy GO, Sato Y, Kitani K (1992) (-)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: The sex and age-related differences in the optimal dose in the rat. Exp Neurol 116:286-294.
29. Chan-Palay V (1975) Fine structure of labelled axons in the cerebellar cortex and nuclei of rodents and primates after intraventicular infusions with tritiated serotonin. Anat Embryol 148:235-265.
30. Cohen GP, Pasik B, Cohen A, Leist C, Mitileneou MD, Yahr M(1984) Pargyline and (-)deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1, 2, 3, 6- Tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 106:209-210.
31. Connick JH, Hanlon G, Roberts J, France L, Fox PK, Nicholson CD (1992) Multiple sigma binding sites in guinea-pig and rat brain membranes: Gprotein interactions. Br J Pharm 107:726-731.
32. Crane GE (1956) Psychiatric side effects of iproniazid. Am J Psychiatr 112: 494-499.
33. Dabrowsky M (1995) Kandinsky compositions. The Museum of Modern Art, New York.
34. Dalló J, Lekka N, Knoll J (1986a) Age dependent decrease of copulatory activity and its correction by (-)deprenyl in male rats. In: Borsy J, Kerecsen L, György L (eds)Dopamine, ageing and diseases. Pergamon Press, Akadémiai Kiadó, Budapest, pp 35-38.
35. Dalló J, Lekka N, Knoll J (1986b) The ejaculatory behavior of sexually sluggish male rats treated with (-)deprenyl, apomorphine, bromocriptine and amphetemine. Pol J Pharmacol Pharm 38: 251-255.
36. Davis BA, Boulton AA (1994) The trace amines and their acidic metabolites in depression an overview. Prog Neuro-Psychopharmacol Biol Psychiatry 18:17-45.
37. Descarries L, Léger L (1978) Serotonin nerve terminals in the locus coeruleus of the adult rat. 3. In: Garattini S, Pujol JF, Samanin R (eds) Interactions between putative neurotransmitters in the brain. Raven Press, New York, pp 355-367.
38. Descarries L, Watkins KC, Lapierre Y (1977) Noradrenergic axon terminals in the cerebral cortex of rat. Topmetric ultrastructural analysis. Brain Res 133:197-222.
39. Dobbs SM, Dobbs RJ, Charlett A (1996) Multi-centre trials: U-turns by bandwagons and the patient left by the wayside. Br J Clin Pharmacol 42:143- 145.
40. Eckert B, Gottfries CG, Knorring L, Oreland L, Wilbert A, Winblad B (1980) Brain and platelet monoamine oxidase in schizoprenics and cycloid psychotics. Prog Neuropsychopharmacol 4:57-68.
41. Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, Shaw KM, Stern GM, Kumar P (1978) Deprenyl administration in man; a selective monoamine oxidase B inhibitor without the "cheese effect". Psychopharmacology 57:33-38.
42. minan M, Gill S, Samii A (2003) Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: Systematic review and meta-analysis of observational studies. Brit Med J 327:128-131.
43. Falsaperla A, Monici Preti PA, Oliani C (1990) Selegiline versus oxiracetam in patients with Alzheimer-type dementia. Clin Ther 12:376-384.
44. Finnegan KT, Skratt JJ, Irvin I, DeLanney LE, Langston JW (1990) Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. Eur J Pharmacol 184:119-126.
45. Fischer E, Heller B, Miró AH (1968) β-Phenylethylamine in human urine. Arzneimittelf 18:1486.
46. Fischer E, Spatz H, Heller B, Reggiani H (1972) Phenethylamine content of human urine and rat brain, its alterations in pathological conditions and after drug administration. Experientia 15:307-308.
47. Fowler CJ, Oreland L, Marcusson J, Winblad B (1980) Titration of human brain monamine oxidase -A and -B by clorgyline and L-deprenyl. Naun-Schmied Arch Pharmacol 311:263-272.
48. Fowler CJ, Wiberg A, Oreland L, Marcusson J, Windlab B (1980) The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 49:1-20.
49. Greenshow AJ (1989) Functional interactions of 2-phenylethylamine and of tryptamine with brain catecholamines: Implications for psychotherapeutic drug action. Prog Neuro-Psychopharmacol Biol Psychiatry 13:431- 443.
50. Grundman M(2000) Vitamin E and Alzheimer disease: The basis for additional clinical trials. Am J Clin Nutr 71:630s-636s.
51. Hamabe W, Fujita R, Yasusa T, Yoneda F, Yoshida A, Ueda H (2000) (-)1- (Benzofuran-2-yl)-2-propylaminopentane shows survival effect on cortical neurons under serum-free condition through sigma receptors. Cell Mol Neurobiol 20:695-702.
52. Hársing RG, Magyar K, Tekes K, Vizi ES, Knoll J (1979) Inhibition by (-)- deprenylofdopamineuptake in rat striatum:Apossible correlationbetween dopamine uptake and acetylcholine release inhibition. Pol J Pharmacol Pharm 31:297-307.
53. Hauger RL, Skolnick P, Paul SM (1982) Specific [3H] beta-phenylethylamine binding sites in rat brain. Eur J Pharmacol 83:147-148.
54. Healy D (1996) The psychopharmacologists I. Altman, London, Weinham, New York, Tokyo, Melbourne, Madras.
55. Healy D (1998) The psychopharmacologists II. Altman, London, Weinham, New York, Tokyo, Melbourne, Madras.
56. Healy D (2000) The psychopharmacologists III. Arnold. London, Oxford University Press Inc., New York.
57. Helmer C, Joly P, Letenneur L, Commenges D, Dartigues JF (2001) Mortality with dementia: Results froma French prospective community-based cohort. Am J Epidemiol 154:642-648.
58. Hilgard ER (1948) Theories of learning. Appleton Century Crofts, New York.
59. Hökfelt T(1968) Invitro studies oncentral and peripheralmonoamine neurons at the ultrastructural level. Z Zellforsch 91:1-74.
60. Hy LX, Keller DM(2000) Prevalence of AD among whites: A summary by levels of severity. Neurology 55:198-204.
61. Iacopino V, Peel M (2002) The medical documentation of torture. Greenich Medical Media, London.
62. Janssen PA, Leysen JE, Megens AA, Awouters HF (1999) Does phenylethylamine act as an endogenous amphetamine in some patients? Int J Neuropsychopharmacol 2:229-240.
63. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in human brain. Biochem Pharmacol 17:1285-1297.
64. Kaufman S (2001)Modern hatreds: The symbolic politics of ethnic war. Cornell Univ Press.
65. Kelemen K, Longo VG, Knoll J, Bovet D (1961) The EEG arousal reaction in rats with extinguishable and non-extinguishable conditioned reflexes. Electroenc Clin Neurophysiol 13:745-751.
66. Kitani K, Kanai S, Sato Y, Ohta M, Ivy GO, Carrillo MC(1992) Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats. Further evidence. Life Sci 52:281-288.
67. Kitani K, Minami C, Isobe K, Maehara K, Kanai S, Ivy GO, Carrillo MC (2002) Why (-)deprenyl prolongs survival of experimental animals: Increase of anti-oxidant enzymes inbrainandotherbodytissuesaswell asmobilization of various humoral factors may lead to systemic anti-aging effects. Mech Aging Dev 123:1087-1100.
68. Kline NS (1958) Clinical experience with iproniazid (marsilid). J Clin Exp Psychophathol 19:72-81.
69. Knoll B (1961) Certain aspects of the formation of temporary connections in comparative experiments on mice and rats. Acta Physiol Hung 20:265-275.
70. Knoll B (1968) Comparative physiological and pharmacological analysis of the higher nervous function of mice and rats (in Hungarian). Candidate of Sciences Thesis (Ph.D equivalent). Hungarian Academy of Sciences, Budapest.
71. Knoll J (1956) Experimental studies on the higher nervous activity of animals. V. The functional mechanismof the active conditioned reflex. Acta Physiol Hung 10:89-100.
72. Knoll J (1957) Experimental studies on the higher nervous activity of animals. VI. Further studies on active reflexes. Acta Physiol Hung 12:65-92.
73. Knoll J (1969) The theory of active reflexes. An analysis of some fundamental mechanisms of higher nervous activity. Hungarian Academy of Sciences, Budapest; Hafner Publishing Company, New York.
74. Knoll J (1976) Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In:Wolstenholme GES, Knight J (eds) Monoamine oxidase and its inhibition. Ciba foundation Symposium 39 (new series), Elsevier, Amsterdam, pp 131-161.
75. Knoll J (1978) The possible mechanism of action of (-)deprenyl in Parkinson's disease. J Neural Transm 43:177-198.
76. Knoll J (1981a) Can the suicide inactivation of MAO by deprenyl explain its pharmacological effects? In: Singer TP, Ondarza N (eds)Molecular basis of drug action. Elsevier, Amsterdam, pp 185-201.
77. Knoll J (1981b) The pharmacology of selective MAO inhibitors. In: Youdim, MBH, Paykel, ES (eds)Monoamine oxidase inhibitors: The state of the art. John Wiley and Sons, London, pp 45-61.
78. Knoll J (1981c) Further experimental support to the concept that (-)deprenyl facilitates dopaminergic neurotransmission in the brain. In: Kamijo K, Usdin E, Nagatsu T (eds) Monoamine oxidase. basic and clinical frontiers. Excerpta Medica, Amsterdam, pp 230-240.
79. Knoll J (1982) Selective inhibition of B type monoamine oxidase in the brain: A drug strategy to improve the quality of life in senescence. In: Keverling Buisman JA (ed) Strategy in drug research. Elsevier, Amsterdam, pp 107-135.
80. Knoll J (1983) Deprenyl (selegiline). The history of its development and pharmacological action. Acta Neurol Scand Suppl 95:57-80.
81. Knoll J (1985) The facilitation of dopaminergic activity in the aged brain by (-)deprenyl. A proposal for a strategy to improve the quality of life in senescence. Mech Ageing Dev 30:109-122.
82. Knoll J (1986a) Striatal dopamine, aging and deprenyl. In: Borsy J, Kerecsen L, György L (eds)Dopamine, ageing and diseases. Pergamon Press, Akadémiai Kiadó (Hungarian Academy of Sciences), Budapest, pp 7-26.
83. Knoll J (1986b) The pharmacology of (-)deprenyl. J Neural Transm Suppl 22:75-89.
84. Knoll J (1986c) Role of B-type monoamine oxidase inhibition in the treatment of Parkinson's disease. An update. In: Shah NS, Donald AG (eds)Movement disorders. Plenum Press, New York, pp 53-81.
85. Knoll J (1987) R-(-)Deprenyl (Selegiline, Movergan®) facilitates the activity of the nigrostriatal dopaminergic neuron. J Neural Transm 25:45-66.
86. Knoll J (1988) The striatal dopamine dependency of lifespan in male rats. Longevity study with (-)deprenyl. Mech Ageing Dev 46:237-262.
87. Knoll J (1989) The pharmacology of selegiline/(-)deprenyl.Acta Neurol Scand 126:83-91.
88. Knoll J (1990) Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity. Adv Neurol 53:425-429.
89. Knoll J (1992a) Pharmacological basis of the therapeutic effect of (-)deprenyl in age-related neurological diseases. Med Res Rev 12:505-524.
90. Knoll J (1992b) (-)Deprenyl-medication: A strategy tomodulate the age-related decline of the striatal dopaminergic system. JAGS 40:839-847.
91. Knoll J (1993a)The pharmacological basis of the beneficial effect of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. J Neural Transm Suppl 40:69-91.
92. Knoll J (1993b) The pharmacological basis of the therapeutic of (-)-deprenyl in age-related neurological diseases. In: Szelenyi I (ed) Inhibitors of monoamine oxidase B. Pharmacology and clinical use in neurodegenerative disorders. Birhkäuser Verlag, Basel, pp 145-168.
93. Knoll J (1993c) Some clinical implication of MAO-B inhibition. In: Yasuhara H, Parvez SH, Oguchi K, Sandler M, Nagatsu T (eds) Monoamine oxidase: basic and clinical aspects. VSP Utrecht, The Netherlands, pp 197-217.
94. Knoll J (1994)Memories of my 45 years inresearch. Pharmacol Toxicol 75:65-72.
95. Knoll J (1995) Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes. Biomed Pharmacother 49:187-195.
96. Knoll J (1996) (-)Deprenyl (selegiline) in Parkinson's disease: A pharmacologist's comment. Biomed Pharmacother 50:315-317.
97. Knoll J (1998) (-)Deprenyl (selegiline) a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol Toxicol 82:57-66.
98. Knoll J (2001) Antiaging compounds: (-)Deprenyl (Selegiline) and (-)1- (benzofuran-2-yl)-2-propylaminopentane, (-)BPAP, a selective highly potent enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. CNS Drug Rev 7:317-345.
99. Knoll J (2003) Enhancer regulation/endogenous and synthetic enhancer compounds: A neurochemical concept of the innate and acquired drives. Neurochem Res 28:1187-1209.
100. Knoll J, Magyar K (1972) Some puzzling effects of monoamine oxidase inhibitors. Adv. Bioch Psychopharmacol 5:393-408.
101. Knoll J, Miklya I (1994) Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition. Arch Int Pharmacodyn Thér 328:1-15.
102. Knoll J, Miklya I (1995) Enhanced catecholaminergic and serotoninergic activity in rat brain fromweaning to sexual maturity. Rationale for prophylactic (-)deprenyl (selegiline) medication. Life Sci 56:611-620.
103. Knoll J, Kelemen K, Knoll B(1955a)Experimental studies onthe higher nervous activity of animals. 1. Amethod for the elaboration of a non-extinguishable conditioned reflex in the rat. Acta Physiol Hung 8:327-345.
104. Knoll J, Kelemen K, Knoll B (1955b) Experimental studies on the higher nervous activity of animals. 2. Differences in the state of function of the cells constituting the cortical representationof the unconditioned reflex in extinguishable and non-extinguishable conditioned reflexes. Acta Physiol Hung 8:347-367.
105. Knoll J, Kelemen K, Knoll B(1955c)Experimental studies onthe higher nervous activity of animals. 3. Experimental studies on the active conditioned reflex. Acta Physiol Hung 8:369-388.
106. Knoll J, Kelemen K, Knoll B (1956) Experimental studies on the higher nervous activity of animals. 4. A method for elaborating and studying an active conditioned feeding reflex. Experimental analysis of differences between active conditioned defensive and feeding reflexes. Acta Physiol Hung 9:99-109.
107. Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B (1965) Phenylisopropyl methyl propinylamine (E-250) a new psychic energizer. Arch Int Pharmacodyn Thér.155:154-164.
108. Knoll J, Vizi ES, Somogyi G (1968) Phenylisopropylmethylpropinylamine (E- 250), a monoamine oxidase inhibitor antagonizing the effects of tyramine. Arzneimittelf 18:109-112.
109. Knoll J, Yen TT, Dalló J (1983) Long-lasting, true aphrodisiac effect of (-)deprenyl in sexually slugg ish old male rats. Mod Probl Pharmacopsychiatry 19:135-153.
110. Knoll J, Dalló J, Yen TT (1989) Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl. Life Sci 45:525-531.
111. Knoll J, Knoll B, Török Z, Timár J, Yasar S (1992a) The pharmacology of 1- phenyl-2-propylaminopentane (PPAP), a deprenyl-derived new spectrum psychostimulant. Arch int Pharmacodyn Thér 316:5-29.
112. Knoll J, Tóth V, Kummert M, Sugár J (1992b) (-)Deprenyl and (-)parafluorodeprenyl- Treatment prevents age-related pigment changes in the substantia nigra. A TV-image analysis of neuromelanin. Mech Ageing Dev 63:157-163.
113. Knoll J, Yen TT, Miklya I (1994) Sexually low performing male rats dies earlier than their high performing peers and (-)deprenyl treatment eliminates this difference. Life Sci 54:1047-1057.
114. Knoll J, Miklya I, Knoll B, Markó R, Kelemen K (1996a) (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons. Life Sci 58: 817-827.
115. Knoll J, Knoll B, Miklya I (1996b) High performing rats are more sensitive toward catecholaminergic activity enhancer (CAE) compounds than their low performing peers. Life Sci 58:945-952.
116. Knoll J, Miklya I, Knoll B, Markó R, Rácz D (1996c) Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain. Life Sci 58:2101-2114.
117. Knoll J, Yoneda F, Knoll B, Ohde H, Miklya I (1999) (-)l-(Benzofuran-2-yl)- 2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Br J Pharm 128:1723-1732.
118. Knoll J, Miklya I, Knoll B, Dalló J (2000) Sexual hormones terminate in the rat the significantly enhanced catecholaminergic/serotoninergic tone in the brain characteristic to the post-weaning period. Life Sci 67:765-773.
119. Knoll J, Miklya I, Knoll B (2002a) Stimulation of the catecholaminergic and serotoninergic neurons in the rat brain by R-(-)-1-(benzofuran-2-yl)-2- propylaminopentane, (-)-BPAP. Life Sci 71:2137-2144.
120. Knoll J, Miklya I, Knoll B, Yasusa T, Shimazu S, Yoneda F (2002b) 1-(Benzofuran- 2-yl)-2-(3, 3, 3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged. Life Sci 71:1975-1984.
121. Koffka K (1935) Principles of gestalt psychology. Harcourt, Brace, New York.
122. Köhler W(1947) Gestalt psychology. Liveright, New York.
123. Kuhn R (1957) Über die Behandlung depressiver Zustände mit einem Imonodibenzilderivat. Schweitz Med Wschr 36:1135-1139.
124. Kuhn W, Muller T (1996) The clinical potential of deprenyl in neurological and psychiatric disorders. J Neural Transm Suppl 48:85-93.
125. Larsen JP, Boas J, Erdal JE (1999) Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian- Danish Study Group. Eur J Neurol 6:539-547.
126. Lees AJ (1991) Selegiline hydrochloride and cognition. Acta Neurol Scand Suppl 136:91-94.
127. Lees AJ (1995) Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br Med J 311:1602-1607.
128. Libet B(1973)Electrical stimulationof cortex in humansubjects, and conscious memory aspects. In: Iggo A (ed) Handbook of sensory physiology, vol 2. Springer-Verlag, Berlin, Heidelberg, New York, pp 743-790.
129. Levene M, Roberts P (eds) (1999) Massacre in history. Berghahn Books, New York.
130. Lockhart BP, Lestage PJ (2003) Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: Why? when? which? Exp Gerontol 38:119-128.
131. Lorente de No R (1935) Electrical excitability of motoneurones. J Cell Comp Physiol 7:46-71.
132. Mann JJ, Gershon S (1980) A selective monoamine oxidase-B inhibitor in endogenous depression. Life Sci 26:877-882.
133. Mantle TJ, Garrett NJ, Tipton KF (1976) The development of monoamine oxidase in rat liver and brain. FEBS Lett 64:227-230.
134. Martin C (1977) Sexual activity in the aging male. In: Money J, Musaph H(eds) Handbook of sexology. Elsevier, Amsterdam, pp 813-824.
135. Martini E, Pataky I, Szilágyi K, Venter V (1987) Brief information on an early phase-II studywith (-)deprenyl indementedpatients. Pharmacopsychiatry 20:256-257.
136. Maruo J, Yoshida A, Shimohira I, Matsuno K, Mita S, Ueda H (2000) Binding of [35S] GTPγS stimulated by (+)pentazocine, sigma receptor agonist, is abundant in the guinea pig spleen. Life Sci 67:599-603.
137. McGeer EG, McGeer PL, Wada JK (1971) Distribution of tyrosine hydroxylase in human and animal brain. J Neurochem 18:1647-1658.
138. McGrath PJ, Stewart JW, Harrison W, Wagner S, Nunes EN, Quitkin FM (1989) A placebo-controlled trial of L-deprenyl in atypical depression. Pschopharmacol Bull 25:63-67.
139. Mendlewicz J, Youdim MB (1983) L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: A double blind evaluation. Br J Psychiatry 142:508-511.
140. Miklya I, Knoll J (2003) Analysis of the effect of (-)-BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Life Sci 72:2915-2921.
141. Miklya I, Knoll B, Knoll J (2003a) A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline) α-tocopherol was ineffective in the DATATOP study. Life Sci 72:2641-2648.
142. Miklya I, Knoll B, Knoll J (2003b) An HPLC tracing of the enhancer regulation in selected discrete brain areas of food deprived rats. Life Sci 72:2923-2930.
143. Milgram MW, Racine RJ, Nellis P, Mendoca A, Ivy GO (1990) Maintenance on L-(-)deprenyl prolongs life in aged male rats. Life Sci 47:415-420.
144. Mink JW, Thach WT (1993) Basal ganglia intrinsic circuits and their role in behavior. Curr Opinion in Neurobiol 3:950-957.
145. Miyoshi K (2001) Parkinson's disease. Nippon Rinsho 59:1570-1573.
146. Monteverde A, Gnemmi P, Rossi F, Monteverde A, Finali GC (1990) Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clin Ther 12:315-322.
147. Morishima-Kawashima M, Iharra Y (2002) Alzheimer's disease: β-amyloid protein and tau. J Neurosci Res 70:392-401.
148. Moruzzi G, Magoun HW(1949) Brain stem reticular formation and activation of the EEG. Electroenceph Clin Neurophysiol 1:455-473.
149. Moss FA (1924) Study of animal drives. J Exp Psychol 7:165-185.
150. Myttyla VV, Sotaniemi KA, Vourinen JA, Heinonen EH (1992) Selegiline as initial treatment in de novo parkinsonian patiens. Neurology 42:339-343.
151. Nakajima T, Kakimoto Y, Sano I (1964) Formation of β-phenylethylamine in mammalian tissue and its effect on motor activity. J Pharm 143:319-325.
152. Neve RL, Robakis NK (1998) Alzheimer's disease: A re-examination of the amyloid hypothesis. Trends in Neurosci 21:15-19.
153. Nguyen TV, Juorio AV (1989) Binding sites for brain trace amines. Cell Mol Neurobiol 9:297-311.
154. Nguyen TV, Paterson IA, Juorio AV, Greenshow AJ, Boulton AA (1989) Tryptaminereceptors: Neuro chemical and electro physiological evidence for postsynaptic and functional binding sites. Brain Res 476:85-93.
155. Nies A, Robinson DS, Davis JM, Ravaris CL (1973) Changes in monoamine oxidase with aging, In: Eisdorfer C, Fann WE(eds) Psychopharmacology of aging (Advances in behavioral biology). Plenum Press, New York, pp 41-54.
156. Nussbaum RL, Ellis CE (2003) Alzheimer's disease and Parkinson's disease. N Engl J Med 348:1356-1364.
157. Ohta K, Ohta M, Mizuta I, Fujinami A, Shimazu S, Sato N, Yoneda F, Hayashi K, Kuno S (2002) The novel catecholaminergic and serotonergic activity enhancer R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane up-regulates neurotrophic factor synthesis in mouse astrocytes. Neurosci Lett 328: 205-208.
158. Oka T, Yasusa T, Ando T, Watanabe M, Yoneda F, Ishida T, Knoll J (2001) Enantioselective synthesis and absolute configurationof (-)1-(benzofuran- 2-yl)-2-propylaminopentane, (-)-BPAP, a highly potent and selective catecholaminergic activity enhancer. Bioorg Med Chem 9:1213-1219.
159. Olanow CW, Godbold JH, Koller W (1996) Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Patients taking selegilinemay have received more levodopa than necessary. Br Med J 312:702-703.
160. Parkinson Study Group (1989) Effect of (-)deprenyl on the progression disability in early Parkinson's disease. New Engl J Med 321:1364-1371.
161. Parkinson Study Group (1993) Effect to tocopherol and (-)deprenyl on the progression of disability in early Parkinson's disease. New Engl J Med 328: 176-183.
162. Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment of Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 39:37-45.
163. Pavlov IP (1955) Pawlowsche Mit two chkolloquien. Akademie Verlag, Berlin, p 492.
164. Penfield W(1955) The permanent record of the stream of consciousness. Acta Psychologica 11:47-69.
165. Phillips PEM, Stuber GD, Heien MLAV, Wightman RM, Carelli RM(2003) Subsecond dopamine release promotes cocaine seeking. Nature 422:614-617.
166. Ponto LL, Schultz SK (2003) Ginkgo biloba extract: Review of CNS effects. Ann Clin Psychiatry 15:109-119.
167. Popper RK, Eccles JC (1977) The self and its brain. An argument for interactionism. Springer International, Berlin.
168. Premont RT, Gainetdinov RR, Caron MG (2001) Following the trace of elusive amines. Proc Natl Acad Sci USA 98:9474-9475.
169. Quitkin RT, Liebowitz MR, Stewart JW, McGrath PJ, Harrison W, Rabkin JG, Markowitz J, Davis SO (1984) L-Deprenyl in atypical depression. Arch Gen Psychiatry 41:777-781.
170. Rashid MH, Matsumoto T, Mizuno K, Watanabe M, Sato N, Yoneda F, Ueda H (2001) Nociceptive responses by deprenyl derivative, (-)BPAP through metabotropic sigma receptor. Pharmacol Rev Com 11:335-342.
171. Richards JG, Lorez HP, Tranzer JP (1973) Indolealklylamine nerve terminals in cerebral ventricles, identification by electron microscopy and fluorescence histochemistry. Brain Res 57:277-288.
172. Richter CP (1927) Animal behavior and internal drives. Quart Rev Biol 2: 307-343.
173. Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson's disease. J Neural Transm 38:277-301.
174. Rinne JO, Röyttä M, Paljärvi L, Rummukainen J, Rinne UK (1991) Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease. Neurology 41:859-861.
175. Ritter JL, Alexander B (1997) Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Ann Clin Psychiarty 9:7-13.
176. Robinson DS, Davis JM, Nies A, Ravaris CL, Sylwester D (1971) Relation of sex and aging to monoamine oxidase activity of human brain, plasma and platelets. Arch Gen Psychiatry 24:536-539.
177. Robinson DS, Davis JM, Nies A, Colburne JR, Runney WE, Shaw DM (1972) Aging, monoamines, and monoamine oxidase levels. The Lancet i:290-291.
178. Saavedra JM (1974) Enzymatic isotopic assay for and presence of beta-phyenylethylamine in brain. J Neurochem 22:211-216.
179. Saavedra JM (1989) Catecholamines II. In: Trendelenburg U, Weiner N (eds) Handbook of experimental pharmacology. Springer-Verlag, Berlin Heidelberg New York, pp 181-201.
180. Sabelli HC, Mosnaim AD (1974) Phenylethylamine hypothesis of affective behavior. Am J Psychiat 131:695-699.
181. Sabelli HC, Javaid JI (1995) Phenylethylaminemodulation of affect: Therapeutic and diagnostic implication. J Neurophsychiatry Clin Neurosci 7:6-14.
182. Sabelli HC, Fawcett J, Gusovsky F, Javaid JI, Wynn P, Edwards H, Jeffriess H, Kravitz HJ (1986) Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplements. Clin Psychiatry 47:66-70.
183. Sandler M, Glover V, Ashford A, Stern GM (1978) Absence of "cheese effect" during deprenyl therapy: Some recent studies. J Neural Transm 43:209-215.
184. Sano M, Ernesto C, Klauber MR (1996) Rationale and design of a multicenter study of selegiline and α-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer Dis Assoc Disord 10:132-140.
185. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 336:1216-1222.
186. Satoi M, Matsuishi T, Yamada S, Yamashita Y, Ohtaki E, Mori K, Kiikonen R, Kato H, Percy AK (2000) Decreased cerebrosbinal fluid levels of betaphenylethylamine in patients with Rett snydrome. Ann Neurol 47:801-803.
187. Schumacher M, Weil-Engerer S, Liere P, Robert F, Franklin RJ, Garcia- Segura LM, Lambert JJ, Mayo W, Melcangi RC, Parducz A, Suter U, Carelli C, Baulieu EE, Akwa Y (2003) Steroid hormones and neurosteroids in normal and pathological aging of the nervous system. Prog Neurobiol 71:3-29.
188. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766.
189. Shih JC (1979) Monoamine oxidase in aging human brain. In: Singer TP, Korff RW, Murphy DL (eds) Monoamine oxidase: Structure, function and altered functions. Academic Press, New York, pp 413-421.
190. Shimazu S, Miklya I (2004) Pharmacological studies with endogenous enhancer substances: β-phenylethyamine, tryptamine, and their synthetic derivatives. Progr Neuro-Psychopharmacol Biol Psychiatry 28:421-427.
191. Shimazu S, Takahata K, Katsuki H, Tsunekawa H, Tanigawa A, Yoneda F, Knoll J, Akaike A(2001) (-)-1-(Benzofuran-2-yl)-2-proplyaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release. Eur J Pharm 421:181-189.
192. Shimazu S, Tanigawa A, Sato N, Yoneda F, Hayashi K, Knoll J (2003) Enhancer substances: Selegiline and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane, [(-)-BPAP] enhance the neurotrophic factor synthesis on cultured mouse astrocytes. Life Sci 72:2785-2792.
193. Skinner BF (1938) The behavior of organisms. Appleton Century Crofts, New York.
194. Stamford JA, Justice JB Jr (1996) Probing brain chemistry. Anal Chem 68:359A- 363A.
195. Standaert DG, Young AB(1996) Treatment of central nervous systemdegenerative disorders. In:Hardman JG, Limbird LE (eds) Goodman&Gilman's. The pharmacological basis of therapeutics, 9th edn. McGraw-Hill, New York, pp 503-519.
196. Strolin Benedetti M, Keane PE (1980) Differential changes in monoamine oxidase A and B activity in the aging brain. J Neurochem 35:1026-1032.
197. Student AK, Edwards DJ (1977) Subcellular localization of types A and B monoamine oxidase in rat brain. Biochem Pharm 26:2337-2342.
198. Tanner CM, Goldmann SM(1996) Epidemiology of Parkinson's disease. Neurol Clin 14:317-335.
199. Tariot PN, Cohen RM, Sunderland T, Newhouse PA, Yount D, Mellow AM (1987) L-(-)Deprenyl in Alzheimer's disease. Arch Gen Psychiatry 44:427- 433.
200. Tennyson V, Heikkila R, Mytilineou C, Coté L, Cohen G (1974) 5-Hydroxydopamine 'tagged' neuronal boutons in rabbit neostriatum: Interrelationship between vesicles and axonal membrane. Brain Res 82:341-348.
201. Tetrud JW, Langston JW (1989) The effect of (-)deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245:519-522.
202. Thomas T (2000) Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol Aging 21:343-348.
203. Thorndike EL (1898) Animal intelligence: An experimental study on the associative processes in animals. Psychol Rev 2(8) (monograph suppl).
204. Thorndike EL (1911) Animal intelligence. Macmillan, New York.
205. Thorndike EL (1940) Psychology of wants, interests and attitudes. Macmillan, New York.
206. Tokuyama S, Hirata K, Yoshida A, Maruo J, Matsuno K, Mita S, Ueda H (1999) Selective coupling of mouse brain metabotropic sigma receptor with recombinant Gi1. Neurosci Lett 268:85-88.
207. Tolman EC (1932) Purposive behaviour in animals and in man. Appleton Century Crofts, New York.
208. TomT, Cummings JL (1998) Depression in Parkinson's disease. Pharmacological characteristics and treatment. Drugs Aging 12:55-74.
209. Tóth V, Kummert M, Sugár J, Knoll J (1992) A procedure for measuring neuromelanin in neurocytes by a TV-image analyser. Mech Ageing Dev 63: 215-221.
210. Tringer L, Haits G, Varga E (1971) The effect of (-)E-250, (-)L-phenyl-isopropylmethyl- propinyl-amine HCl, in depression. In: Leszkovszky G (ed) V. Conferentia HungaricaproTherapia et Investigatione inPharmacologia. Akadémiai Kiadó, Budapest, pp 111-114.
211. Uchtomsky AA (1945) Cited by Knoll J (1969) The theory of active reflexes. Hungarian Academy of Sciences, Budapest, Hafner Publishing Company, New York, p 75.
212. Ueda H, Inoue M (2000) In vivo signal transduction of nociceptive responses by kyotorphin (tyrosis-arginin) through Gαi- And inositol triphosphatemediated Ca2+ influx. Molec Pharm 57:108-115.
213. Usdin E, Sandler M (eds) (1976) Trace amines and the brain. Marcel Dekker, New York.
214. Varga E (1965) Vorläufiger Bericht über die Wirkung des Präparats E-250 (Phenyl-Isopropyl-Methyl-Propinylamine-Chlorhydrat) In: Dumbovich B (ed) III. Conferentia Hungarica pro Therapia et Investigatione in Pharmacologia. Akadémiai Kiadó (Hungarian Academy of Sciences), Budapest, pp 197-201.
215. Varga E, Tringer L (1967) Clinical trial of a new type of promptly acting psychoenergetic agent (phenyl-isopropylmethyl-propinylamine HCl, E-250). Acta Med Acad Sci Hung 23:289-295.
216. Vizuete ML, Steffen V, Ayala A, Cano J, Machado A (1993) Protective effect of deprenyl against 1-methyl-4-phenylpiridinium neurotoxicity in rat striatum. Neurosci Lett 152:113-116.
217. Walker SE, Shulman KI, Tailor SA, Gardner D (1996) Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J Clin Psychopharmacol 16:383-388.
218. Wilner J, Le Fevre HF, Costa E (1974) Assay by multiple ion detection of phenylethylamine and phenylethanolamine in rat brain. J Neurochem 23: 857-859.
219. Wu RM, Chiuech CC, Pert A, Murphy DL (1993) Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur J Pharmacol 243:241-247.
220. Yoneda F, Moto T, Sakae M, Ohde H, Knoll B, Miklya I, Knoll J (2001) Structureactivity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, (-)BPAP, a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Bioorg Med Chem 9:1197-1212.
221. Youdim MB (1980) Monoamine oxidase inhibitors as anti-depressant drugs and as adjunct to L-dopa therapy of Parkinson's disease. J Neural Transm Suppl 16:157-161.
222. Zeller EA, Barsky J (1952) In vivo inhibition of liver and brain monoamine oxidase by 1-isonicotinyl-2-isopropylhydrazine. Proc Soc Exp Biol Med 81:459-468.
223. Zeller EA, Barsky J, Fouts JE, Kirchheimer WF, Van Orden LS(1952) Influenceof isonicotinic acid hydrazide (INH) and 1-isonicotinic 2-isopropylhydrazide (IIH) on bacterial and mammalian enzymes. Experientia 8:349-350.
224. Zesiewicz TA, Gold M, Chari G, Hauser RA (1999) Current issues in depression in Parkinson's disease. Am J Geriat Psychiat 7:110-118.